Where Is Epilepsy More Common in the World

Outline

Epilepsy is a chronic disease of the brain defined by an enduring (i.e., persisting) sensitivity to generate seizures, unprovoked by some contiguous CNS insult, and by the neurobiologic, cognitive, psychological, and sociable consequences of capture recurrences. Epilepsy affects both sexes and all ages with world-wide distribution. The prevalence and the relative incidence of epilepsy are slightly high in men compared to women and tend to peak in the older, reflective the higher absolute frequency of stroke, neurodegenerative diseases, and tumors therein age-grouping. Focal seizures are more plebeian than generalized seizures both in children and in adults. The aetiology of epilepsy varies according to the sociodemographic characteristics of the affected populations and the extent of the diagnostic workup, but a documented do is still lacking in about 50% of cases from high-income countries (HIC). The overall prognosis of epilepsy is favorable in the majority of patients when measured by seizure exemption. Reports from low/centre-income countries (LMIC; where patients with epilepsy are for the most part untreated) give prevalence and remission rates that lap those of HICs. As the incidence of epilepsy appears higher in most LMICs, the overlapping prevalence commode be explained past misdiagnosis, acute symptomatic seizures and premature mortality. Studies have consistently shown that about half of cases tend to achieve prolonged gaining control absolution. Even so, more recent reports on the long-term prognosis of epilepsy have identified differing prognostic patterns, including archeozoic and tardy remission, a relapsing-remitting flow, and even a worsening course (characterized by remittance followed aside relapse and unceasing seizures). Epilepsy intrinsically carries a downhearted mortality lay on the line, but significant differences in mortality rates are expected when comparison relative incidence and prevalence studies, children and adults, and persons with disorder and symptomatic seizures. Sharp unexplained death is most frequent in people with generalized tonic-clonic seizures, nocturnal seizures, and do drugs refractory epilepsy.

Epilepsy is one of the most park neurological diseases and affects people of all ages, races, social classes, and geographical locations. Epilepsy is a disease of the brain defined by an enduring sensitivity to generate seizures and by the neurobiologic, cognitive, mental, and social consequences of ictus recurrences [1]. The epileptic seizures are recurrent paroxysmal events characterised by conventional activity alterations that reverberate the underlying neural mechanisms of the disease. The differential diagnosis of epilepsy encompasses a number of clinical conditions characterized aside transient alteration of awareness and/surgery behavior. In most cases, the disease can Be diagnosed through a careful history or away the observation of a ictus. Although an etiologic broker can be identified, inactive in near matchless half of cases, the cause is obscure [2]. A variable genetic predisposition to manifest seizures and the differing dispersion of some environmental hazard factors tin can explain the heterogeneity of the frequency, flow, and consequences of the disease in the world. In plus to the return of seizures, the underlying lawsuit and the adverse effects of treatment have neurologic, cognitive, psychological, and elite group consequences that significantly affect the timbre of life of the stricken individuals and make the disease a complex nosographic entity.

Definitions and Terminology

While all people with epilepsy experience seizures, not all individuals with seizures have epilepsy. Brain disorder seizures may also occur later an acute accent central systema nervosum (CNS) insult (noesis, general, toxic, Oregon metabolic). These events (acute accent symptomatic operating theater provoked seizures) are intended as acute manifestations of the diss [3] and Crataegus oxycantha not recur when the subjacent cause has been removed operating theatre the acute phase has elapsed [4]. According to the Worldwide League Against Epilepsy (ILAE), epilepsy is defined by any of the following conditions: (1) at least 2 unprovoked (or involuntary) seizures occurring >24 h apart; (2) one unprovoked (operating room reflex) seizure and a chance of further seizures similar to the generalized recurrence adventure (at the least 60%) after 2 unprovoked seizures, occurring over the next 10 years; and (3) diagnosis of an epilepsy syndrome [5]. Withal, for the purpose of conducting universe-based studies, the ILAE Epidemiology Commission advises that epilepsy be defined as 2 or Thomas More motiveless seizures occurring leastways 24 h obscure [6].

An wanton seizure is a seizure occurring in the absence of precipitating factors. Unprovoked seizures include events occurring in the absence of recognized etiological or risk factors (idiopathic and cryptogenic seizures), in patients with antecedent unfluctuating (nonprogressing) CNS insults (remote diagnostic seizures), or in those with progressive Systema nervosum centrale abnormalities, like brain tumors or degenerative conditions (progressive symptomatic seizures).

Raptus onset can be point (seizures arising in one hemisphere of the mastermind), generalized (seizures originating in both hemispheres simultaneously), and unknown [7]. Focal seizures are top-secret according to whether awareness (a marker for cognisance) is intact or impaired. Focal and generalized seizures are also divided into motor and nonmotor.

Open epilepsy is defined by regular treatment with antiepileptic medications or when the most recent seizure has occurred within the endmost 5 years [6].

Status epilepticus (Southeast) is an epileptic seizure that is sufficiently protracted or repeated at sufficiently brief intervals so atomic number 3 to produce an enduring brain disease condition. SE can induce longsighted-terminus consequences including neuronal injury or dying and alteration of neuronal networks, depending on the character and length of seizures. A new diagnostic classification of SE has been recently proposed [8].

Sudden upset end in epilepsy (SUDEP) is the abrupt, unexpected, witnessed or unwitnessed, nontraumatic, and nondrowning death in patients with epilepsy, with OR without evidence for a seizure and excluding registered SE, in which postmortal examination does non show a toxicologic or anatomic cause of death [9]. In most cases, SUDEP is triggered by a seizure, and seizure-induced cardiopulmonary alterations are a plausible possibility.

Measures of the frequency of epilepsy include relative incidence, prevalence, and mortality; measures of the burden of epilepsy are the disability-adjusted life-geezerhood (DALYs) and their components, the years of life damned, and the years of living with disability.

Relative incidence of Acute Symptomatic Seizures

The median incidence of needlelike symptomatic seizures is 29–39 per 100,000 per twelvemonth [10]. Incisive symptomatic seizures predominate in the youngest age class (under 1 class of get on) and in the elderly. Fever, traumatic brain trauma (TBI), cerebrovascular disease, dose climb-down, infection, and biological process insults are the commonest causative factors.

Incidence of Epilepsy

In a systematic review and meta-analysis of incidence studies, the pooled incidence rate of epilepsy was 61.4 per 100,000 person-years (95% CI 50.7–74.4) [11]. The relative incidence was higher in low/middle-income countries (LMIC) than in high-top-income countries (HIC), 139.0 (95% CI 69.4–278.2) vs. 48.9 (95% CI 39.0–61.1). This can embody explained away the disparate structure of populations at risk and a greater exposure to perinatal jeopardy factors, high rates of CNS infections, and TBI in LMIC. The incidence of epilepsy is also higher in the lowest socioeconomic classes in HIC and, within the same universe, multitude of differing ethnic origin [12]. Differences can be likewise explained past methodological issues, such as more stringent case verification and the exclusion of separated and acute grounds seizures in or s studies.

Prevalence of Epilepsy

The prevalence of epilepsy differs importantly among countries depending on the local dispersion of risk and cause factors, the act of seizures at diagnosis and if considering only active epilepsy (gymnastic preponderance) or including as wel cases in remission (lifetime prevalence). In the Fiest et alia. [11], the overall lifespan preponderance of epilepsy was 7.60 per 1,000 universe (95% CI 6.17–9.38) and was higher in LMIC (8.75 per 1,000; 95% CI 7.23–10.59) than in HIC (5.18 per 1,000; 95% CI 3.75–7.15). The point prevalence of active epilepsy was 6.38 per 1,000 (95% CI 5.57–7.30). The median level prevalence of quick epilepsy in LMIC was 6.68 (95% CI 5.45–8.10) and in HIC was 5.49 (4.16–7.26). In selected populations, preponderance estimates also vary and be given to be higher in individuals of certain ethnicities [13], mass in poor health, and socially deprived subjects [14]. Along with issues in the analyze design, the demographic structure of the study population, the preponderance of environmental risk factors, and the quality of wellness management john be implicated.

Incidence and Prevalence of Epilepsy by Sex and Eld

Incidence and preponderance of epilepsy are slightly high in men than in women [11]. The remainder might beryllium explained by the divers prevalence of the nigh common take chances factors and the concealment of the condition in women for sociocultural reasons in certain regions [15].

The relative incidence of epilepsy is higher in the youngest and oldest age-groups [11], with estimates of 86 per 100,000 per year in a healthy-defined population in the first yr old, a course to decrease to about 23–31 per 100,000 in people aged 30–59 age, and a later increase up to 180 per 100,000 in the over 85 long time-group [16]. In children, the incidence of epilepsy is highest in the first year of living and declines to full-grown levels by the end of 10 days of age [17]. In LMIC, epilepsy peaks in children; this may cost a leave of under-ascertainment of the precondition in older individuals as well as the demographic structure of the country.

Lineament Trends of Epilepsy

In the last decades, the age-limited incidence of epilepsy has decreased with time in the youngest mature-groups, belik due to improvements in perinatal care, better sanitation, and increased control of health problem diseases [18]. In contrast, the incidence has increased in the elderly, likely imputable improved living expectancy (with parallel increase of aging-related epileptogenic conditions, such as stroke, tumors, and neurodegenerative disorders) and increased ascertainment of the disease in this age-radical.

Incidence and Prevalence by Seizure Type

Central seizures are the predominant seizure type both in children and in adults [16, 19]. The most common type of focal seizure is a focal visually impaired cognizance capture (accounting for approximately 36% of all people with seizures) [16]. In most LMIC, however, the predominant types reported are generalized tonic-clonic seizures [20], a reflection of under-ascertainment of the new seizure types, likely due to a want of acknowledgment and diagnostic tools. The relative incidence of Southeast has been found to vary from 6.8 to 41 per 100,000 per year [21] with a bimodal dispersion (peaks in children <1 year and the elderly). The all-embracing range can be explained by the universe at lay on the line, the truth of the diagnosis, the differing statistical distribution of the implicit in causes, and the inclusion or exclusion of acute symptomatic seizures.

Incidence and Prevalence aside Epilepsy Type

In a population-based study done 20 years past in a USA population [22], focal epilepsies of unknown aetiology were the all but green group in the great unwashe newly diagnosed with epilepsy (17.5 cases per 100,000 per year), followed by symptomatic partial epilepsies (central epilepsies of structural operating theater metabolic etiology according to the new ILAE classification) [23] (17.2), unidentified epilepsies (epilepsies of unacknowledged aetiology; 9.7), symptomatic/cryptogenic epilepsies (epilepsies of structural surgery metabolic aetiology/unknown etiology; 4.0), idiopathic generalized epilepsies (3.7), and idiopathic fond epilepsies (i.e., generalized and point epilepsies of presumed genetic origin; 0.2). The proportion of epilepsies with unknown etiology has remained substantially unchanged in more recent years, at to the lowest degree in HIC [24].

In children, age at attack was importantly correlate with etiology. Approximately half had a documentable aetiology. Of them, 28% were structural/metabolic, which predominated when seizures started before 12 months of mature, and 22% were presumedly genetic, virtually believable associated with older get on at attack [19]. A specific epilepsy syndrome could be detected in 28% of cases at first diagnosing.

Prognosis of Epilepsy

Epilepsy is a treatable condition, with up to 80% entering prolonged periods of raptus remission and rising to 50% continuing to be seizure-free after treatment discontinuation [25, 26]. However, reports from several LMIC (where treatment gap is high) give prevalence and remission rates clinker-built to HIC [27]. As in most LMIC, the incidence of epilepsy is higher than in HIC and increased mortality can explain only in part the difference betwixt incidence and prevalence, misdiagnosis and acute symptomatic seizures must be also considered.

Studies in recently diagnosed patients take consistently shown that 55–68% of cases tend to achieve prolonged gaining control remission [27]. However, in a long population-based study done in patients with puerility-onset epilepsy, differing remitment patterns were seen. Half of the patients entered fatal remittal, without reversion, and one-fifth after relapse. About one-third had a poor outcome in damage of absolute petit mal epilepsy of remission OR relapsing seizures after periods of remission [26]. These patterns stimulate been confirmed in part by others [28-31].

The risk of relapse afterward a first unprovoked ictus in population-based studies was clean consonant with 36–37% rates at 1 year and 43–45% rates at 2 years [27]. In a systematic brushup, the average return risk was 51% (95% CI 49–53%) [32]. After a first motiveless seizure, the probability of a relapse decreases with time. Approximately 50% of recurrences occur within 6 months. A documented aetiology of the seizure and an abnormal (epileptiform and/or slow) electroencephalogram (Encephalogram) pattern are the 2 near consistent predictors of recurrence. The pooled 2-yr return risk is last for an idiopathic surgery cryptogenic first seizure with a normal EEG (24%; 95% Curie 19–29%), arbitrate for a remote symptomatic seizure (48%; 95% CI 34–62%) with normal EEG or an idiopathic/cryptogenic seizure with an abnormal EEG (48%; 95% CI 40–55%), and highest with a remote symptomatic seizure with an abnormal Encephalogram (65%; 95% CI 55–76%) [32]. Interictal EEG epileptiform abnormalities tend to be related with a high gamble of raptus return than non-epileptiform abnormalities. Seizures occurring during sleep are also connected with a higher risk of recurrence some in children and in adults. Focal seizures are also related to with a high hazard of recurrence, even afterwards controlling for etiology and EEG abnormalities. A positive correlation between seizure relapse and family history of seizures has been confirmed in patients with idiopathic or cryptogenic first seizures. Chronicle of acute symptomatic seizures prior to the premier unprovoked seizure has been found to increase the put on the line of relapse, patc evidence is inconclusive or lacking for arouse, age, and SE.

The prognosis of untreated epilepsy give the sack be assessed simply in LMIC where epilepsy is largely untreated (treatment gap ranging from 70 to 94%) [33]. In a population-based study done in Ecuador, the cumulative annual incidence rate was 190 per 100,000 and the prevalence pace of active epilepsy was 7 per 1,000, which implies a remission rate of at to the lowest degree 50% [34]. Confusable preponderance rates of active epilepsy were found in other countries [35, 36]. These findings lend support to the hypothesis that spontaneous remission of epilepsy is a common event.

Aetiology of epilepsy is the strongest prognostic predictor for gaining control recurrence. In a distinct US population, symptomatic epilepsies had a importantly lower accidental of 5-year remission compared to upset epilepsies (30 vs. 42% at 15 years) and patients with neurological disfunction salute at birth had the last find of remission [25]. Other prognostic indicators enclosed ictus typewrite and EEG epileptiform abnormalities. Lour remission rates in patients with symptomatic epilepsies were found also in Europe [27].

Every bit proposed by Sander [37], epilepsy patients can be classified into 4 contrary prognostic groups: (1) Superior prognosis (astir 20–30% of the total) with high chance of spontaneous remission; these let in kind focal epilepsies, benign myoclonic epilepsy in infancy, and epilepsies provoked away specific modes of energizing, that is, reflex epilepsies; (2) Operative prognosis (just about 30–40%) with easy pharmacological control and possible action of spontaneous remission; these let in childhood absence epilepsy and some focal epilepsies; (3) Iffy prognosis (about 10–20%), which may respond to drugs, but tend to relapse after treatment withdrawal; these include immature myoclonic epilepsy and most focal epilepsies (symptomatic OR cryptogenic); (4) Pitiful prognosis (about 20%) in which seizures tend to repeat despite intensifier treatment; these include epilepsies associated with congenital neurological defects, modernised neurological disorders, and some symptomatic or cryptogenic partial epilepsies. This compartmentalization is still valid flatbottomed aft the advent of more sophisticated diagnostic techniques and after the introduction of some new antiepileptic drugs.

Mortality rate of Epilepsy

Epilepsy per se carries a low mortality rate risk, but significant differences in mortality rates are expected when comparison incidence and prevalence studies, children and adults, and persons with idiopathic and characteristic seizures [38]. Eastern Samoa with preponderance and incidence, epilepsy mortality reflects the quality of case ascertainment, the truth of the information on causes of death and the survey methods [6]. Hoi polloi with epilepsy are at an multiplied gamble of death than the general universe [38]. Among deaths attributable to epilepsy or seizures, important immediate causes include SUDEP, Sou'-east, undesigned injuries, and suicide.

In HIC, standardized mortality ratio ranges from 1.6 to 3.0 [38]. In LMIC, the corresponding ratio is 19.8 (95% CI 9.7–45.1) [39]. Standardized mortality ratio is slightly higher in men than in women and in children and adolescents, in people with epilepsies imputable documented aetiology, and in those reporting less adherence to treatment. Indirect causes of death in LMIC include not only drowning and burns just also lack of access to wellness facilities and preventable causes.

The incidence of SUDEP among people with epilepsy is 1.2 per 1,000 person-years (95% CI 0.9–1.5) and ranges from 1.1 (95% CI 0.5–2.3) in children under age 16 years to 1.3 (95% CI 0.9–1.8) in adults afterward the maturat of 50 years [40]. The John R. Major risk factors admit generalized tonic-convulsion seizures, nocturnal seizures, and persistence of seizures. Freedom from seizures, particularly generalized tonic-convulsion, is associated with decreased risk and nocturnal superintendence is protective [41].

Burden of Epilepsy

Reported to the 2016 Global Saddle of Disease Collaborators [18], epilepsy represents a relevant fraction of the worldwide disease burden, account statement for about 46 million hoi polloi. Nearly 80% of people with epilepsy domicile in LMIC, where rates of epilepsy preponderance and incidence are higher than in HIC [42]. The differences are likely due to differing causes, a high incidence of injuries, and lack of approach to healthcare.

In 2016, epilepsy accounted for >13 million DALYs and was responsible 0.5% of the total disease burden [18]. In terms of historic period-standardized DALY rates for all neurological disorders by Global Load of Disease region in 2016, epilepsy stratified second to ordinal depending on the geographic region. The burden of idiopathic epilepsy (i.e., imputable a genetic cause or when diagnostic assessment did not reveal a causative factor) was highest in eastern, west, and southern sub-Saharan Africa, midmost Asia, nuclear and Andean Latin America, and Southeast Asia (Fig. 1).

Fig. 1.

Age-standardised preponderance (×100,000) of idiopathic epilepsy away country, 2016. With permission from Global Burden of Disease 2016 Epilepsy Collaborators [18].

/WebMaterial/ShowPic/1156343

Age-standardized DALYs were 182.6 per 100,000 universe, 163.6 per 100,000 population for women, and 201.2 per 100,000 population for men. The high DALY rates in work force than in women were due to higher old age of life lost rates. Betwixt 1990 and 2016, in that location was a nonsignificant 6.0% increase in the historic period-standardized prevalence of idiopathic epilepsy, but a significant decrease in age-standardised mortality rates (–24.5%) and age-standardised DALY rates (–19.4%).

Betwixt 1990 and 2016, a significant reduction was observed in the mortality rate in people with idiopathic epilepsy and, less, a reduction was found in DALY rates [18]. This finding probably reflects improvements in access to health facilities and treatment, which in turn may lead to a lesser severity of the disease and lower risk of death.

The Change of the Population Wellness and Its Impact on the Epidemiology of Epilepsy

The data on the global burden of epilepsy have clearly demonstrated that, contrary to other nonsubjective conditions, the disease presents a decreasing trend, mostly explained by a earthshaking diminution of mortality. A significant decrease of catching diseases as a reflection of best sanitation and the introduction of preventive measures leads to the reduction of many situation risk factors and epileptogenic conditions. Better healthcare is also followed by increased survival and, in turn, by a longer life expectancy. The progressive aging of the worldwide population is accompanied past a shift of age-specific incidence and preponderance of epilepsy with a progressive decrease of the disease in the youngest age-groups and a corresponding increase in the elderly. A bettor control of preventable causes of brain disorder seizures, which mostly include pre-/perinatal injuries, Systema nervosum centrale infections and infestations, TBI, and stroke [43], will be followed aside a decrease of these clinical conditions but an increase in senescent-related diseases (in particular, CNS tumors and Alzheimer disease and other dementias).

Conclusions and In store Directions

Despite the decrease in the disease burden, epilepsy is still an important cause of disability and mortality. If applied to epidemiological studies, the change in the definition of epilepsy, which now includes a significant number of cases with single unprovoked seizures, will affect incidence, preponderance, and mortality of epilepsy in the time to come. Nevertheless, the collection of information on epilepsy in representative population samples and using standardised methods will strengthen the estimates and testament provide accurate findings in countries for which we presently have no or sparse data and if additive information are collected connected severity, causes, and treatments. Sizable gains in reduction the encumbrance of epilepsy power be unsurprising from improved access to existing treatments in low-income countries and from the ontogeny of unweathered impelling drugs worldwide.

Disclosure Affirmation

Dr. Ettore Beghi reports grants from UCB-Pharma, SOBI and the European nation Ministry of Health.

References

Fisher RS, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions planned by the Internationalist League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). Epilepsia. 2005 Apr;46(4):470–2.
Neligan A, Hauser Washington, Sander JW. The epidemiology of the epilepsies. Handb Clin Neurol. 2012;107:113–33.
Beghi E, Carpio A, Forsgren L, Hesdorffer DC, Malmgren K, Sander JW, et al. Recommendation for a definition of acute symptomatic seizure. Epilepsia. 2010 Apr;51(4):671–5.
Hesdorffer DC, Benn EK, Cascino GD, Hauser WA. Is a introductory acute characteristic seizure epilepsy? Mortality and risk for recurrent seizure. Epilepsia. 2009 May;50(5):1102–8.
Black cat RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger Atomic number 58, et al. ILAE official report card: a matter-of-fact clinical definition of epilepsy. Epilepsia. 2014 Apr;55(4):475–82.
Thurman DJ, Beghi E, Begley Cerium, Alban Berg AT, Buchhalter JR, Ding D, et al.; ILAE Commission on Epidemiology. Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia. 2011 Sep;52 Suppl 7:2–26.
Black cat RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen Atomic number 26, et al. Operational classification of seizure types past the International League Against Epilepsy: Aide-memoire of the ILAE Commission for Classification and Terminology. Epilepsia. 2017 Apr;58(4):522–30.
Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer Internet Explorer, Shinnar S, et al. A definition and classification of status epilepticus – Report of the ILAE Project Force on Classification of Condition Epilepticus. Epilepsia. 2015 Oct;56(10):1515–23.
Nashef L, So EL, Ryvlin P, Tomson T. Unifying the definitions of sudden unexpected expiry in epilepsy. Epilepsia. 2012 Feb;53(2):227–33.
Hauser WA, Beghi E. World-class seizure definitions and ecumenical incidence and fatality rate. Epilepsia. 2008;49 Suppl 1:8–12.
Fiest KM, Sauro KM, Wiebe S, Patten Atomic number 51, Kwon CS, Dykeman J, et al. Prevalence and incidence of epilepsy: A systematised review and meta-psychoanalysis of international studies. Neurology. 2017 January;88(3):296–303.
Beghi E, Hesdorffer D. Prevalence of epilepsy – an transcendent measure. Epilepsia. 2014 Jul;55(7):963–7.
Kelvin Ea, Hesdorffer DC, Bagiella E, Andrews H, Pedley TA, Shih Terrestrial dynamical time, et aluminum. Prevalence of self-rumored epilepsy in a multiracial and multiethnic residential district in NY City. Epilepsy Res. 2007 Dec;77(2-3):141–50.
Kaiboriboon K, Bakaki PM, Lhatoo Mount Rushmore State, Koroukian S. Incidence and preponderance of tempered epilepsy among poor health and baritone-income Americans. Neurology. 2013 May;80(21):1942–9.
Bharucha NE, Bharucha EP, Bharucha AE, Bhise Av, Schoenberg BS. Prevalence of epilepsy in the Parsi community of Bombay. Epilepsia. 1988 Mar-Apr;29(2):111–5.
Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unmotivated seizures in Rochester, Gopher State: 1935-1984. Epilepsia. 1993 May-Jun;34(3):453–68.
Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disord. 2015 Jun;17(2):117–23.
GBD 2016 Clinical neurology Collaborators. Globular, regional, and home gist of medicine disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lance Neurol. 2019;18:357–75.
Wirrell EC, Grossardt Brigate Rosse, Wong-Kisiel LC, Nickels KC. Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study. Epilepsy Res. 2011 Jun;95(1-2):110–8.
Senanayake N, Román GC. Epidemiology of epilepsy in underdeveloped countries. Bull Cosmos Health Organ. 1993;71(2):247–58.
Chin RF, Neville BG, Scott RC. A systematic review of the epidemiology of status epilepticus. Eur J Neurol. 2004 Dec;11(12):800–10.
Zarrelli MM, Beghi E, Rocca WA, Hauser WA. Incidence of encephalopathy syndromes in Rochester, Minnesota: 1980-1984. Epilepsia. 1999 Dec;40(12):1708–14.
Scheffer IE, Berkovic S, Capovilla G, Little Mo Connolly MB, French J, Guilhoto L, et al. ILAE categorisation of the epilepsies: Position newspaper publisher of the ILAE Commission for Compartmentalization and Terminology. Epilepsia. 2017 April;58(4):512–21.
Giussani G, Franchi C, Messina P, Nobili A, Beghi E; EPIRES Grouping. Preponderance and incidence of epilepsy in a clear population of Septrional Italia. Epilepsia. 2014 Oct;55(10):1526–33.
Annegers JF, Hauser WA, Elveback LR. Remission of seizures and relapse in patients with epilepsy. Epilepsia. 1979 Dec;20(6):729–37.
Sillanpää M, Schmidt D. Biological history of treated childhood-onset epilepsy: prospective, long-run population-based study. Brain. 2006 Mar;129(Pt 3):617–24.
Beghi E, Giussani G, Drum sander JW. The natural history and prognosis of epilepsy. Brain disease Disord. 2015 September;17(3):243–53.
Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Neurology. 2012 May;78(20):1548–54.
Shorvon SD, Goodridge DM. Longitudinal cohort studies of the prognosis of epilepsy: contribution of the Position Pandemic Drill Study of Epilepsy and other studies. Brain. 2013 Nov;136(Pt 11):3497–510.
Berg AT, Rychlik K. The path of childhood-onset epilepsy over the first two decades: a expected, long study. Epilepsia. 2015 Jan;56(1):40–8.
Giussani G, Canelli V, Bianchi E, Erba G, Franchi C, Nobili A, et al.; EPIRES Group. Long-run prognosis of epilepsy, prophetic patterns and drug resistance: a universe-based hit the books. Eur J Neurol. 2016 Jul;23(7):1218–27.
Berg AT, Shinnar S. The risk of seizure return undermentioned a first unprovoked seizure: a quantitative review. Neurology. 1991 Jul;41(7):965–72.
Mbuba CK, Ngugi AK, Isaac Newton Chromium, James Earl Carter JA. The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. Epilepsia. 2008 Sep;49(9):1491–503.
Placencia M, Shorvon SD, Paredes V, Bimos C, Sander JW, Suarez J, et al. Epileptic seizures in an Andean region of Ecuador. Incidence and prevalence and regional variation. Mentality. 1992 Jun;115(Pt 3):771–82.
Watts AE. The normal history of untreated epilepsy in a rural community in Africa. Epilepsia. 1992 May-Jun;33(3):464–8.
Nicoletti A, Sofia V, Vitale G, Bonelli SI, Bejarano V, Bartalesi F, et aluminum. Natural history and deathrate of chronic epilepsy in an untreated universe of rural Bolivia: a follow-skyward afterwards 10 age. Epilepsia. 2009 Oct;50(10):2199–206.
Sander JW. Some aspects of prospect in the epilepsies: a review. Epilepsia. 1993 Nov-Dec;34(6):1007–16.
Thurman DJ, Logroscino G, Beghi E, Hauser WA, Hesdorffer DC, Newton CR, et al.; Epidemiology Delegacy of the Planetary Conference Against Epilepsy. The burden of untimely mortality of epilepsy in high-income countries: A systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia. 2017 Jan;58(1):17–26.
Levira F, Thurman DJ, Sander JW, Hauser WA, Hesdorffer DC, Masanja H, et aliae.; Epidemiology Commission of the Transnational League Against Epilepsy. Early mortality of epilepsy in low-down- and middle-income countries: A systematic review from the Deathrate Task Hale of the Foreign League Against Epilepsy. Epilepsia. 2017 Jan;58(1):6–16.
Sveinsson O, Andersson T, Carlsson S, Tomson T. The incidence of SUDEP: A nationwide population-based cohort study. Neurology. 2017 Jul;89(2):170–7.
Harden C, Tomson T, Gloss D, Buchhalter J, Cross JH, Donner E, et al. Practice guideline summary: Sudden unpredicted death in epilepsy incidence rates and risk factors: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Clinical neurology. 2017 Apr;88(17):1674–80.
Meyer AC, Dua T, Master of Arts J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bull World Health Organ. 2010 Apr;88(4):260–6.
Thurman DJ, Begley Common Era, Carpio A, Helmers S, Hesdorffer DC, Mu J, et al. The primary prevention of epilepsy: A story of the Bar Task Force of the International League Against Epilepsy. Epilepsia. 2018 May;59(5):905–14.

Author Contacts

Ettore Beghi, MD

Department of Neuroscience, Laboratory of Neurological Disorders

Istituto di Ricerche Farmacologiche Mario Negri IRCCS

Via Giuseppe La Masa 19, IT–20156 Milano (Italy)

Netmail ettore.beghi@marionegri.it

Clause / Publication Inside information

First-Varlet Preview

Abstract of Review

Received: September 03, 2019
Uncontroversial: September 28, 2019
Published online: December 18, 2019
Issue release date: March 2020

Number of Print Pages: 7
Number of Figures: 1
Number of Tables: 0

ISSN: 0251-5350 (Mark)
eISSN: 1423-0208 (Online)

For additive information: https://www.karger.com/NED

Copyright / Do drugs Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any shape surgery by hook or by crook, electronic or mechanical, including photocopying, transcription, microcopying, or by whatever information storage and retrieval system, without permission in writing from the publisher.
Drug Dose: The authors and the publisher throw exerted every try to ensure that drug selection and dosage set forth in this text edition are in accord with current recommendations and practice at the time of publication. However, in view of current research, changes in politics regulations, and the incessant flow of information relating to dose therapy and drug reactions, the reader is urged to check the package insert for each do drugs for any changes in indications and dose and for added warnings and precautions. This is peculiarly important when the recommended agent is a radical and/operating theatre infrequently employed drug.
Disclaimer: The statements, opinions and data restrained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the issue is non a warranty, endorsement, or approving of the products or services advertised Beaver State of their effectiveness, lineament or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons surgery property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Where Is Epilepsy More Common in the World

Source: https://www.karger.com/Article/Fulltext/503831